Discover
GLPG
Galapagos N.V.
27.98
1 x 20.48
1 x 35.21
bid
ask
+
0.00
0.00%
11:58 AM
timesize
| Ytd | -14.43% | |
| 1y | -3.08% |
27.50
day range
28.09
24.74
52 week range
37.78
| Open | 27.50 | Prev Close | 27.98 | Low | 27.50 | High | 28.09 | Mkt Cap | 1.84B |
| Vol | 2.38K | Avg Vol | 187.56K | EPS | 8.71 | P/E | 3.21 | Forward P/E | -26.56 |
| Beta | 0.25 | Short Ratio | 6.95 | Inst. Own | 22.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 30.32 | 200-d Avg | 32.15 | 1yr Est | 27.23 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.97 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -1.27 | 0.25 | 1.52 | 119.69% |
| 2026-02-23 | 2025-12 | 1 | 16.38 | 15.38 | 1538.00% |
| 2025-11-05 | 2025-09 | -0.2 | -3.59 | -3.39 | -1696.35% |
| 2025-07-23 | 2025-06 | -0.67 | -1.89 | -1.22 | -182.27% |
| 2025-04-23 | 2025-03 | -0.23 | -2.47 | -2.24 | -973.91% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-02-25 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-11-07 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-10-22 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2025-10-21 | Leerink Partners | Upgrade | Market Perform | Outperform |
| 2025-02-14 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| 2025-01-23 | Barclays | Downgrade | Equal-Weight | Underweight |
Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Gilead Sciences Inc | 16.71M | 463.30M | 25.35% |
| 2025-12-30 | Tang Capital Management, LLC | 3.92M | 108.74M | 5.95% |
| 2025-12-30 | Madison Avenue Partners, LP | 2.21M | 61.37M | 3.36% |
| 2025-12-30 | EcoR1 Capital, LLC | 1.67M | 46.23M | 2.53% |
| 2025-12-30 | Ameriprise Financial, Inc. | 1.45M | 40.24M | 2.20% |
| 2025-12-30 | Prosight Management, Lp | 1.07M | 29.79M | 1.63% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-02-27 | Columbia Funds Series Trust-Columbia Overseas Value Fund | 714.75K | 19.82M | 1.08% |
| 2025-12-30 | Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core | 385.91K | 10.70M | 0.59% |
| 2026-03-30 | iShares Trust-iShares Core MSCI EAFE ETF | 314.77K | 8.73M | 0.48% |
| 2026-03-30 | iShares Trust-iShares Biotechnology ETF | 272.46K | 7.56M | 0.41% |
| 2026-03-30 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 130.42K | 3.62M | 0.20% |
| 2025-12-30 | Segall Bryant & Hamill Trust-SBH Small Cap Value Fund | 94.15K | 2.61M | 0.14% |